Oryzon Genomics - Advancing on multiple clinical fronts in Q

Oryzon has reported Q123 results highlighting its near-term strategic priorities, including a favourable interim analysis of its lead asset study, the Phase IIb PORTICO study (vafidemstat, central nervous

Related Keywords

, Gefallene Big Techs , Oryzon , Genomics , Dvancing , Multiple , Linical , Fronts ,